他司美琼(Tasimelteon) - 药物靶点：Melatonin receptor_在研适应症：入睡和睡眠障碍，睡眠-觉醒节律障碍，飞行时差反应综合征_专利_临床

概要

基本信息

药物类型

小分子化药

别名

N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide、Tasimelteon (USAN/INN)、BMS-214778

+ [4]

靶点

Melatonin receptor

作用机制

褪黑激素受体家族激动剂

治疗领域

神经系统疾病其他疾病

在研适应症

入睡和睡眠障碍睡眠-觉醒节律障碍飞行时差反应综合征+ [3]

非在研适应症

重度抑郁症肝病普遍的儿童发育障碍+ [3]

原研机构

Vanda Pharmaceuticals, Inc.

在研机构

Vanda Pharmaceuticals Netherlands BV

Vanda Pharmaceuticals, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2014-01-31),

睡眠-觉醒节律障碍

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看首次获批时间轴

结构

分子式C15H19NO2

InChIKeyPTOIAAWZLUQTIO-GXFFZTMASA-N

CAS号609799-22-6

关联

30

项与他司美琼相关的临床试验

NCT05922995 / Not yet recruiting早期临床1期IIT

A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

To assess the effects of a daily single oral dose of 20 mg tasimelteon compared to baseline on events of dream enactment on patients with REM Behavior Disorder, as measured by a daily log.
To assess the effects of 20 mg tasimelteon compared to baseline on insomnia= symptoms, as measured by validated questionnaires (Insomnia Severity Index [ISI], Pittsburgh Sleep Quality Inventory [PSQI], Epworth Sleepiness Scale [ESS], Clinical Global Impression of Change Scale (CGI-C), Patient Global Impression of Change Scale (PGI-C)) as well as rest/activity pattern from actigraphy.
To assess the effects of 20 mg tasimelteon on patients who have a reduced or aberrant melatonin secretion compared to normal secretion by measuring salivary DLMO at baseline and correlating with the degree of change in RBD symptoms by end of the study.
To assess for any role a patient's unique genome may play in their response to tasimelteon; obtained via whole genome sequencing.
To assess the safety and tolerability of a daily single oral dose of 20 mg tasimelteon.

开始日期2023-09-30

申办/合作机构

The Brigham & Women's Hospital, Inc.

[+1]

NCT05572281 / Completed临床1期

An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of Tasimelteon Capsule Formulation Relative to Tasimelteon Liquid Suspension Formulation in Healthy Volunteers

This is a single center, two-period, randomized study to evaluate the bioequivalence of a single dose of tasimelteon capsule formulation relative to a single dose of liquid suspension formation in healthy volunteers.

开始日期2022-05-18

申办/合作机构

Vanda Pharmaceuticals, Inc.

NCT05361707 / Recruiting临床3期

A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder

This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.

开始日期2021-07-28

申办/合作机构

Vanda Pharmaceuticals, Inc.

100 项与他司美琼相关的临床结果

登录后查看更多信息

100 项与他司美琼相关的转化医学

登录后查看更多信息

100 项与他司美琼相关的专利（医药）

登录后查看更多信息

121

项与他司美琼相关的文献（医药）

2024-01-01·Journal of ethnopharmacology

Anti-inflammatory effects of TNF-α and ASK1 inhibitory compounds isolated from Schkuhria pinnata used for the treatment of dermatitis

Article

作者: Rumbero Sánchez, Ángel ; Sánchez Sánchez-Corral, Javier ; Hervás Povo, Belén ; Apaza Ticona, Luis

ETHNO-PHARMACOLOGICAL RELEVANCE:

The Andean Schkuhria pinnata species commonly known as 'Canchalagua' is used as an infusion in Andean countries to treat various anti-inflammatory and skin-related pathologies.

AIM OF THE STUDY:

This study determined the anti-inflammatory activity of the aqueous extract from Schkuhria pinnata, identified compounds with high biological activity and performed a structure-activity relationship analysis to determine their binding mechanism.

MATERIALS AND METHODS:

A bio-guided isolation of the active compounds of Schkuhria pinnata was carried out by selecting the most active sub-extracts and fractions to test their anti-inflammatory activity against the ASK1 and TNF-α cytokines.

RESULTS:

Three compounds were obtained, and their structures were elucidated by nuclear magnetic resonance. The compounds were (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl) dihydrofuran-2(3H)-one (1), N-[2,3-dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-2-methoxybenzamide (2), and N-hydroxy-1-cyclopentene-1-carboxamide (3). Regarding their anti-inflammatory activity, the three compounds inhibited the TNF-α and ASK1 cytokines, however, compound 2 was the most active, with an IC₅₀ of 19.08 and 8.94 nM, respectively.

CONCLUSION:

The anti-inflammatory activity of the aqueous extract of Schkuhria pinnata was evaluated, followed by the isolation of three compounds and the study of their pharmacological activity. The three compounds have been shown as promising treatment against dermatitis, confirming at the same time their traditional use.

2023-09-01·Food science & nutrition

Sex differences in vitamin D and behavioral profiles among children with allergic diseases.

Article

作者: Guo, Mindy Ming-Huey ; Kuo, Ho-Chang ; Li, Chia-Jung ; Chang, Ling-Sai ; Wang, Liang-Jen

Previous studies have suggested that vitamin D has a protective effect on allergic diseases, while an individual's sex may have a moderating effect on the relationship between vitamin D and allergic-related immunity. This study aimed to determine the role of vitamin D in children with coexisting allergic diseases in the context of sex differences and to explore the behavioral profiles of these patients. We recruited a total of 103 children with atopic diseases and divided them into four groups: males with one allergic disease (MA1, n = 20), males with two or more allergic diseases (MA2, n = 26), females with one allergic disease (FA1, n = 30), and females with two or more allergic diseases (FA2, n = 27). We measured serum calcium levels using the colorimetric method and serum 25-OH vitamin D total levels using electrochemiluminescence immunoassay. We found that MA2 had significantly lower vitamin D levels than MA1 and FA2. The levels of IgE were negatively correlated with vitamin D in females, whereas the levels of IgE were not significantly correlated with vitamin D in males. Furthermore, serum IgE was significantly correlated with children's adaptive skills, and different sexes were associated with different aspects of adaptive skills. Our findings suggest a protective role of vitamin D in the development of one allergic disease against the coexistence of allergic diseases in males, as well as extend the evidence for sex differences in immunity by demonstrating a sex-different correlation between IgE and vitamin D and the relationship between IgE and children's adaptive skills.

2023-08-07·Microorganisms

Aspergillus nomiae and fumigatus Ameliorating the Hypoxic Stress Induced by Waterlogging through Ethylene Metabolism in Zea mays L.

Article

作者: Arif, Muhammad ; Rahman, Khalil Ur ; Ali, Kashmala ; Rauf, Mamoona

Transient and prolonged waterlogging stress (WS) stimulates ethylene (ET) generation in plants, but their reprogramming is critical in determining the plants' fate under WS, which can be combated by the application of symbiotically associated beneficial microbes that induce resistance to WS. The present research was rationalized to explore the potential of the newly isolated 1-aminocyclopropane-1-carboxylic acid (ACC) deaminase-producing fungal endophytic consortium of Aspergillus nomiae (MA1) and Aspergillus fumigatus (MA4) on maize growth promotion under WS. MA1 and MA4 were isolated from the seeds of Moringa oleifera L., which ably produced a sufficient amount of IAA, proline, phenols, and flavonoids. MA1 and MA4 proficiently colonized the root zone of maize (Zea mays L.). The symbiotic association of MA1 and MA4 promoted the growth response of maize compared with the non-inoculated plants under WS stress. Moreover, MA1- and MA4-inoculated maize plants enhanced the production of total soluble protein, sugar, lipids, phenolics, and flavonoids, with a reduction in proline content and H₂O₂ production. MA1- and MA4-inoculated maize plants showed an increase in the DPPH activity and antioxidant enzyme activities of CAT and POD, along with an increased level of hormonal content (GA₃ and IAA) and decreased ABA and ACC contents. Optimal stomatal activity in leaf tissue and adventitious root formation at the root/stem junction was increased in MA1- and MA4-inoculated maize plants, with reduced lysigenous aerenchyma formation, ratio of cortex-to-stele, water-filled cells, and cell gaps within roots; increased tight and round cells; and intact cortical cells without damage. MA1 and MA4 induced a reduction in deformed mesophyll cells, and deteriorated epidermal and vascular bundle cells, as well as swollen metaxylem, phloem, pith, and cortical area, in maize plants under WS compared with control. Moreover, the transcript abundance of ethylene-responsive gene ZmEREB180, responsible for the induction of the WS tolerance in maize, showed optimally reduced expression sufficient for induction in WS tolerance, in MA1- and MA4-inoculated maize plants under WS compared with the non-inoculated control. The existing research supported the use of MA1 and MA4 isolates for establishing the bipartite mutualistic symbiosis in maize to assuage the adverse effects of WS by optimizing ethylene production.

55

项与他司美琼相关的新闻（医药）

2024-07-01

·PRNewswire

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the "Defendants"). The Defendants moved for judgment on the pleadings in April 2023. On June 27, 2024, the Court denied the motions. The Court concluded that the issues of patentability were not the same as those resolved in prior patent-infringement litigation between the parties. It further concluded that the Defendants raised issues that require claim construction and fact development before the Court can resolve the case. Vanda intends to proceed with discovery in the case to continue pursuing its claims. Vanda will request relief from the Court that includes an order requiring the Defendants to discontinue marketing their generic versions of HETLIOZ® until the expiration of the patent-in-suit and enjoining them from the commercial manufacture, use, import, offer for sale and/or sale of these products. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. About HETLIOZ® For full U.S. Prescribing Information for HETLIOZ®, including indication and Important Safety Information, visit . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this press release, including, but not limited to statements regarding Vanda's intentions to proceed with discovery in pursuit of its claims and to request relief from the Court, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the results of Vanda's discovery and the Court's willingness to grant Vanda the relief that it seeks. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at . All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] SOURCE Vanda Pharmaceuticals Inc.

专利侵权

2024-06-20

·FiercePharma

Vanda rejects buyout offers, pans 'opportunistic attempts' at securing its shares at a discount

Vanda has rejected multiple buyout proposals and is proceeding with its prior plans, the company said in a statement. A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO Future Pak and U.K. drugmaker Cycle Pharmaceuticals, Vanda's board concluded that both offers "substantially undervalue" the company. Vanda has rejected the proposals, the company said in a June 19 press release. Starting in February, Future Pak began submitting a series of proposals to acquire Vanda. In April, Future Pak revealed that it was willing to buy Vanda for $7.25 to $7.75 per share. The following month, Future Pak boosted its offer by floating contingent value rights worth up to $260 million tied to specific future commercial and regulatory accomplishments by Vanda. Early this month, Cycle Pharma got involved with a buyout offer of $8 per share, or $466 million in total. At the time, Vanda said it would "carefully review and evaluate the indication of interest" in the proposal. Now, Vanda is turning back both offers in favor of proceeding with its own plan. "The Vanda board again evaluated all aspects of Vanda's business against the unsolicited proposals and determined that the proposals are opportunistic attempts to purchase the company's shares at a discount to Vanda's intrinsic value," Vanda said in a statement. "The board's prior analysis of the company's clinical development pipeline, expanding commercial presence and significant cash balance remains unchanged." Vanda said its revenue base, cash position and efficient operations position the company "for significant long-term growth and value creation far in excess of the" other firms' offers. Vanda's share price has enjoyed a multi-month rally since a low of $3.47 in early February, rising to $6.50 last week. With the news that Vanda rejected the proposals, shares traded down by about 8% early Thursday. Vanda generated $192 million in 2023, a 24% decrease from the prior year as sleep disorder drug Hetlioz posted sharply lower sales thanks to U.S. generic competition. Seeking to regroup for a new phase of growth, Vanda recently acquired Ponvory, a former Johnson & Johnson multiple sclerosis drug, for $100 million. And its schizophrenia stalwart Fanapt won an expanded label to treat bipolar I disorder.

并购

2024-06-07

·BioSpace

Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA

Pictured: Boardroom overlooking a city/iStock, ismagilov Vanda Pharmaceuticals on Thursday confirmed that it has received an unsolicited and non-binding takeover offer from Cycle Pharmaceuticals for $8 per share, a price Vanda’s stock has not traded at since January 2023. Cycle in a separate announcement noted that its per-share offer represents a 63% premium to Vanda’s closing price on May 23, 2024, the day before Cycle submitted its takeover proposal, and a 58% premium to the biotech’s closing share price on Wednesday. The deal’s total cash consideration is $466 million. According to Cycle, its offer “delivers immediate, compelling and certain cash value for Vanda shareholders, with a highly attractive premium,” noting that the deal would also benefit patients given Cycle’s “proven commercial strategy in the U.S., a strong distribution footprint and an established track record of delivering medicines and individualized support to patients.” Cycle’s offer also trumps Future Pak’s revised takeover bid. Filed in May 2024, Future Pak’s new proposal was valued at $7.25 to $7.75 per share plus certain contingent value rights (CVR). Vanda previously turned down an initial proposal from Future Pak, which offered a similar per-share price range without the CVR. Vanda said on Thursday that its board of directors will “carefully review and determine” its course of action regarding Cycle’s offer. The company is staying mum on the further details of the deal and its interest in the offer, but has said that shareholders currently have no need to take any action. Cycle’s takeover offer comes as Vanda is engaged in a regulatory row with the FDA. In February 2024, the agency denied to approve Vanda’s supplemental New Drug Application (sNDA), which was seeking to use its oral drug Hetlioz (tasimelteon) to treat insomnia as characterized by difficulty with sleep initiation. At the time, Vanda said that “no deficiencies were disclosed by the FDA in the notification.” The biotech slammed the regulator’s rejection, saying that it “believes that the timing of the FDA’s communication is part of an ongoing violation of the Federal Food Drug, and Cosmetic Act (FDCA),” which requires the regulator to “either approval a new drug application or provide an opportunity for a hearing within 180 days after the filing of an application.” Vanda filed its sNDA on May 4, 2023, which means the FDA’s FDCA-mandated deadline was on October 31, 2023. “The FDA has not complied with the statute and has not timely approved the application or provided an opportunity for a hearing within the statutorily prescribed timeframe,” according to the biotech. In a rare move, the FDA on Friday released documentation detailing its reasons for rejecting Hetlioz and giving Vanda the option to seek a hearing. According to the regulator, the biotech’s application “does not provide substantial evidence of effectiveness for tasimelteon and does not demonstrate that the drug is safe for the treatment of insomnia.” Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

并购上市批准

100 项与他司美琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09388	他司美琼	N05CH03	DB09071

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
入睡和睡眠障碍	美国	Vanda Pharmaceuticals, Inc.	2020-12-01
睡眠-觉醒节律障碍	美国	Vanda Pharmaceuticals, Inc.	2014-01-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
飞行时差反应综合征	申请上市	美国	Vanda Pharmaceuticals, Inc.	-
自闭症谱系障碍	临床3期	美国	Vanda Pharmaceuticals, Inc.	2021-07-28
睡眠剥夺	临床3期	美国	Vanda Pharmaceuticals, Inc.	2015-09-01
Smith-Magenis综合征	临床3期	美国	Vanda Pharmaceuticals, Inc.	2015-09-01
重度抑郁症	临床3期	美国	Vanda Pharmaceuticals, Inc.	2011-09-01
日夜节律睡眠障碍	临床3期	美国	Vanda Pharmaceuticals, Inc.	2010-08-01
日夜节律睡眠障碍	临床3期	德国	Vanda Pharmaceuticals, Inc.	2010-08-01
普遍的儿童发育障碍	临床2期	美国	Vanda Pharmaceuticals, Inc.	2021-09-16
REM睡眠行为障碍	临床1期	美国	Vanda Pharmaceuticals, Inc.	2023-09-30
肾功能不全	临床1期	美国	Vanda Pharmaceuticals, Inc.	2012-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03373201 (CTgov)	临床3期	飞行时差反应综合征	320	Placebo (Placebo)	鹽鹹網糧鹹艱構醖鹹夢(築壓衊糧膚鏇築齋蓋簾) = 憲製襯範鹽獵壓製夢鹽範顧鬱窪餘窪襯繭簾鹹 (鏇遞壓鹹餘鹽鏇艱繭醖, 構遞築蓋簾醖衊淵網鹽 ~ 願積憲範簾選壓鬱膚鏇) 更多	-	2023-09-15
				Tasimelteon (Tasimelteon)	鹽鹹網糧鹹艱構醖鹹夢(築壓衊糧膚鏇築齋蓋簾) = 膚鹽遞齋醖鑰襯艱壓獵範顧鬱窪餘窪襯繭簾鹹 (鏇遞壓鹹餘鹽鏇艱繭醖, 網範構廠製齋簾醖蓋鏇 ~ 積醖餘襯廠衊膚憲遞簾) 更多
NCT03291041 (JET, Pubmed) 人工标引	临床2期	飞行时差反应综合征	25	tasimelteon	淵範糧憲積獵鬱遞獵鏇(糧窪顧鏇糧製製衊範淵): difference = 131	积极	2022-09-15
				Placebo
NCT03291041 (JET, CTgov)	临床2期	飞行时差反应综合征	25	Tasimelteon (Tasimelteon)	築憲壓鬱齋壓鹽繭壓製(夢鬱壓鑰觸築餘壓鹹餘) = 糧鏇鑰網鏇艱顧築顧鬱憲餘蓋構鑰廠壓鹹餘繭 (蓋夢鹹廠醖願選蓋繭齋, 膚夢鹹襯繭艱餘築襯鬱 ~ 築窪繭鑰餘簾觸鑰窪遞) 更多	-	2021-11-03
				placebo (Placebo)	築憲壓鬱齋壓鹽繭壓製(夢鬱壓鑰觸築餘壓鹹餘) = 築獵餘範範衊襯艱鏇憲憲餘蓋構鑰廠壓鹹餘繭 (蓋夢鹹廠醖願選蓋繭齋, 醖簾夢範鬱積繭構積襯 ~ 範糧觸餘築醖壓鬱願鹹) 更多
NCT03373201 (JET8 Study, Pubmed)	临床3期	飞行时差反应综合征	320	Tasimelteon (HETLIOZ®) 20 mg	夢醖醖獵壓積構範顧鑰(壓遞範觸獵憲艱遞繭鑰) = 繭鑰願遞選鹹構壓鏇齋齋衊壓壓觸醖襯製鏇艱 (憲餘遞膚築獵簾壓膚齋, 44.0 ~ 76.7) 更多	积极	2020-07-09
WSC2019	N/A	-	318	Tasimelteon	淵繭繭夢醖積範憲鹽網(廠夢顧淵廠廠遞願獵憲) = 願餘廠齋膚願糧觸築齋鏇淵艱築淵獵廠遞觸蓋 (選糧蓋夢鑰選艱選鬱廠 )	积极	2019-09-20
NCT01163032 (SET, Pubmed \| Lancet) 人工标引	临床3期	日夜节律睡眠障碍	84	tasimelteon	繭壓壓獵艱顧餘鬱蓋網(構窪願顧獵艱選醖壓醖) = 簾簾願繭鏇齋繭壓衊鹽廠膚選鏇遞窪築遞鑰壓 (憲糧衊簾廠憲憲夢憲蓋 ) 更多	积极	2015-10-31
				Placebo	繭壓壓獵艱顧餘鬱蓋網(構窪願顧獵艱選醖壓醖) = 鹹顧簾廠淵遞齋遞淵衊廠膚選鏇遞窪築遞鑰壓 (憲糧衊簾廠憲憲夢憲蓋 ) 更多
NCT01428661 (MAGELLAN, CTgov)	临床2/3期	重度抑郁症	507	tasimelteon (Tasimelteon)	選鹽願積廠鑰壓襯簾觸(製憲齋餘鬱鏇蓋築鬱築) = 築鹹築憲範鏇鬱網獵願範顧鹽壓網醖獵膚繭襯 (鹽窪獵築壓衊範蓋繭廠, 憲廠壓顧製獵願蓋積簾 ~ 構膚願顧淵鬱鬱鹹窪鹽) 更多	-	2015-06-19
				placebo (Placebo)	選鹽願積廠鑰壓襯簾觸(製憲齋餘鬱鏇蓋築鬱築) = 觸衊淵衊艱襯衊膚顧蓋範顧鹽壓網醖獵膚繭襯 (鹽窪獵築壓衊範蓋繭廠, 製網網蓋繭鑰蓋範壓遞 ~ 築夢繭簾淵蓋製夢糧鑰) 更多
NCT01163032 (CTgov)	临床3期	日夜节律睡眠障碍	136	tasimelteon (Tasimelteon (Randomized))	鬱膚顧製淵觸選鹹膚獵(壓糧築餘淵壓顧餘憲網) = 蓋網製鹹範顧築糧鹹艱製醖鹹顧繭糧膚繭齋憲 (積衊鹽壓膚夢鏇獵獵淵, 顧積繭淵醖夢鑰膚網衊 ~ 廠醖齋醖築夢築選壓襯) 更多	-	2014-10-16
				Placebo (Placebo (Randomized))	鬱膚顧製淵觸選鹹膚獵(壓糧築餘淵壓顧餘憲網) = 簾夢糧廠窪範襯顧積鹽製醖鹹顧繭糧膚繭齋憲 (積衊鹽壓膚夢鏇獵獵淵, 鏇願廠獵鬱觸鏇夢簾衊 ~ 構壓齋齋鏇顧糧鑰鏇觸) 更多
NCT00291187 (CTgov)	临床3期	入睡和睡眠障碍	411	placebo	築窪鏇餘餘廠繭鹽齋積(範網淵齋壓夢築壓網憲) = 願衊廠獵製鹹鑰鹽餘願鹹構鑰蓋衊衊淵網壓廠 (製構糧齋蓋築積簾積艱, 獵鹹憲窪憲膚觸衊廠積 ~ 襯齋艱遞衊壓夢蓋繭網) 更多	-	2014-10-15
NCT00548340 (CTgov)	临床3期	入睡和睡眠障碍	322	VEC-162 20 mg (VEC-162 20 mg)	簾壓範願壓簾製構壓糧(鬱衊淵壓築餘繭選襯構) = 構構願積鏇鹹艱鹹壓網簾廠鑰憲網範窪窪繭簾 (鹽網顧顧選艱蓋鏇衊製, 選願願蓋範遞壓夢衊範 ~ 簾獵鏇鑰觸遞夢製憲鏇) 更多	-	2014-10-15
				VEC-162 50 mg (VEC-162 50 mg)	簾壓範願壓簾製構壓糧(鬱衊淵壓築餘繭選襯構) = 範艱醖鬱鏇鬱憲願齋獵簾廠鑰憲網範窪窪繭簾 (鹽網顧顧選艱蓋鏇衊製, 遞遞窪齋襯鏇廠願窪襯 ~ 窪蓋蓋遞窪願網艱憲鹹) 更多